GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OWC Pharmaceutical Research Corp (OTCPK:OWCP) » Definitions » Net Current Asset Value

OWC Pharmaceutical Research (OWC Pharmaceutical Research) Net Current Asset Value : $-0.02 (As of Sep. 2019)


View and export this data going back to 2008. Start your Free Trial

What is OWC Pharmaceutical Research Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

OWC Pharmaceutical Research's net current asset value per share for the quarter that ended in Sep. 2019 was $-0.02.

The historical rank and industry rank for OWC Pharmaceutical Research's Net Current Asset Value or its related term are showing as below:

OWCP's Price-to-Net-Current-Asset-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.055
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

OWC Pharmaceutical Research Net Current Asset Value Historical Data

The historical data trend for OWC Pharmaceutical Research's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OWC Pharmaceutical Research Net Current Asset Value Chart

OWC Pharmaceutical Research Annual Data
Trend Dec08 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only 0.02 - - 0.01 -0.06

OWC Pharmaceutical Research Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.06 -0.06 -0.01 -0.02

Competitive Comparison of OWC Pharmaceutical Research's Net Current Asset Value

For the Drug Manufacturers - Specialty & Generic subindustry, OWC Pharmaceutical Research's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OWC Pharmaceutical Research's Price-to-Net-Current-Asset-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, OWC Pharmaceutical Research's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where OWC Pharmaceutical Research's Price-to-Net-Current-Asset-Value falls into.



OWC Pharmaceutical Research Net Current Asset Value Calculation

OWC Pharmaceutical Research's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2018 is calculated as

Net Current Asset Value Per Share(A: Dec. 2018 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(3.516-12.993-0-0)/150.207
=-0.06

OWC Pharmaceutical Research's Net Current Asset Value (NCAV) per share for the quarter that ended in Sep. 2019 is calculated as

Net Current Asset Value Per Share(Q: Sep. 2019 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.695-5.781-0-0)/244.478
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OWC Pharmaceutical Research  (OTCPK:OWCP) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


OWC Pharmaceutical Research Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of OWC Pharmaceutical Research's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


OWC Pharmaceutical Research (OWC Pharmaceutical Research) Business Description

Traded in Other Exchanges
N/A
Address
2 Ben Gurion Street, Ramat Gan, ISR, 5257334
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.
Executives
Asher Zwebner director, officer: CHIEF FINANCIAL OFFICER CDOOR CORPORATION, 20 A REHOV SHAREI TORAH BAYIT VEGAN, JERUSALEM L3 96387

OWC Pharmaceutical Research (OWC Pharmaceutical Research) Headlines